Approval · Notice of Compliance 20924 · 2018
MOVIPREP: Notice of Compliance 20924
Issued May 31, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20924
- Date
- May 31, 2018
- Company
- Aralez Pharmaceuticals Canada Inc.Toronto, Ontario, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Merger - buyout
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MOVIPREP | 02359499 | Marketed |
Medicinal ingredients
- POLYETHYLENE GLYCOL 3350 100 G per PCK
- POTASSIUM CHLORIDE 1.015 G per PCK
- SODIUM ASCORBATE 5.9 G per PCK
- SODIUM CHLORIDE 2.691 G per PCK
- VITAMIN C 4.7 G per PCK
- SODIUM SULFATE ANHYDROUS 7.5 G per PCK